- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses phase 3 trial results for Miebo (perfluorohexyloctane ophthalmic solution), a drug being evaluated for treatment of evaporative dry eye disease in patients with meibomian gland dysfunction.
The phase 3 study compared Miebo (perfluorohexyloctane ophthalmic solution) to a vehicle for the ability to improve signs and symptoms of dry eye. Signs were assessed by corneal staining. After 4 weeks of treatment, Miebo (perfluorohexyloctane ophthalmic solution) demonstrated statistically significant improvements in both signs and symptoms compared with the vehicle, which were sustained through 8 weeks.
Adler notes Miebo produced rapid effects by targeting evaporation, a mechanism of action not previously explored for dry eye treatment. With a favorable safety profile and novel mechanism, Miebo offers an important new treatment option for dry eye disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
